Applicant, as named in the Orange Book
Gilead Sciences Inc
Gilead Sciences Inc · Nasdaq: GILD
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Sovaldi on 11 Jun 2031. 23 products with live protection, 2 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Sovaldi NDA 204671 · 2 strengths sofosbuvir | 11 Jun 2031 patent |
| Sovaldi NDA 212480 · 2 strengths sofosbuvir | 11 Jun 2031 patent |
| Complera NDA 202123 emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate | 14 Jan 2033 patent |
| Odefsey NDA 208351 emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate | 15 Feb 2033 patent |
| Vemlidy NDA 208464 tenofovir alafenamide fumarate | 15 Feb 2033 patent |
| Harvoni NDA 212477 · 2 strengths ledipasvir; sofosbuvir | 14 Mar 2033 patent |
| Genvoya NDA 207561 cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | 6 Apr 2033 patent |
| Stribild NDA 203100 cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | 6 Apr 2033 patent |
| Zydelig NDA 205858 · 2 strengths idelalisib | 2 Sep 2033 patent |
| Epclusa NDA 214187 · 2 strengths sofosbuvir; velpatasvir | 30 Jul 2034 patent |
| Epclusa NDA 208341 · 2 strengths sofosbuvir; velpatasvir | 30 Jul 2034 patent |
| Harvoni NDA 205834 · 2 strengths ledipasvir; sofosbuvir | 30 Jul 2034 patent |
| Descovy NDA 208215 · 2 strengths emtricitabine; tenofovir alafenamide fumarate | 29 Jun 2036 patent |
| Biktarvy NDA 210251 · 2 strengths bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | 8 Nov 2036 patent |
| Vosevi NDA 209195 sofosbuvir; velpatasvir; voxilaprevir | 1 Dec 2037 patent |
| Livdelzi NDA 217899 seladelpar lysine | 13 Mar 2038 patent, carve-out possible |
| Bixlenvo NDA 221104 bictegravir sodium; lenacapavir sodium | 16 Aug 2038 patent |
| Bixlenvo Sunlenca Starter Pack (Copackaged) NDA 221443 bictegravir sodium, lenacapavir sodium; lenacapavir sodium | 16 Aug 2038 patent |
| Yeztugo NDA 220020 lenacapavir sodium | 16 Aug 2038 patent |
| Yeztugo NDA 220018 lenacapavir sodium | 25 Nov 2040 patent, carve-out possible |
| Sunlenca NDA 215974 lenacapavir sodium | 28 Aug 2041 patent, carve-out possible |
| Sunlenca NDA 215973 lenacapavir sodium | 28 Aug 2041 patent, carve-out possible |
| Veklury NDA 214787 remdesivir | 28 Nov 2041 patent |
Recent events
- Descovy · Generic approved · ANDA 214216, Macleods PharmsApproved 7 Apr 2026Detected 25 Oct 2026
- Descovy · Generic approved · ANDA 214173, NatcoApproved 26 Aug 2026Detected 25 Oct 2026
- Viread · Generic approved · ANDA 206157, Micro LabsApproved 18 Dec 2025Detected 25 Oct 2026
- Odefsey · First generic approved · ANDA 214095, ApotexApproved 30 Jan 2026Detected 25 Oct 2026
- Odefsey · Generic approved · ANDA 214095, ApotexApproved 30 Jan 2026Detected 25 Oct 2026
- Vemlidy · Generic tentatively approved · ANDA 214030, Laurus Labs LtdTentative approval 9 Jul 2026Detected 25 Oct 2026
- Complera · Generic approved · ANDA 220232, LaurusApproved 4 Mar 2026Detected 25 Oct 2026
- Zydelig · First generic approved · ANDA 216921, NatcoApproved 17 Feb 2026Detected 25 Oct 2026
- Zydelig · Generic approved · ANDA 216921, NatcoApproved 17 Feb 2026Detected 25 Oct 2026
- Vitekta · Enters 12-month window basis: patentListed date 26 Apr 2027Detected 24 Oct 2026
- Vitekta · Enters 12-month window basis: patentListed date 26 Apr 2027Detected 24 Oct 2026
- Veklury · Exclusivity expires within 90 days PEDExclusivity expires 13 Jan 2027Detected 24 Oct 2026
- Veklury · Exclusivity expires within 90 days PEDExclusivity expires 13 Jan 2027Detected 24 Oct 2026